Long ‐term effects of angiotensin II blockade with irbesartan on inflammatory markers in hemodialysis patients: A randomized double blind placebo controlled trial (SAFIR study)

Discussion Inflammatory biomarkers were neither acutely, nor in the long‐term significantly affected by the ARB irbesartan. Our findings suggest that ARB treatment in HD patients does not offer protective anti‐inflammatory effects.

Source: Hemodialysis International - June 26, 2016 Category: Hematology Authors: Christian D. Peters, Krista D. Kjaergaard, Claus H. Nielsen, Kent L. Christensen, Bo M. Bibby, Jens D. Jensen, Bente Jespersen Tags: Original Article Source Type: research